D. Boral Capital Reaffirms "Buy" Rating for VolitionRx (NYSE:VNRX)

Key Points

• D. Boral Capital has reiterated its "buy" rating for VolitionRx (NYSE:VNRX) with a price target of $5.00.
• The current consensus rating for VolitionRx is "Moderate Buy" with a price target of $3.50, according to MarketBeat data.
• Insiders, including CEO Cameron John Reynolds, purchased a significant number of shares recently, indicating strong confidence in the company's prospects.

D. Boral Capital reiterated their buy rating on shares of VolitionRx (NYSE:VNRX - Free Report) in a research report report published on Friday morning,Benzinga reports. D. Boral Capital currently has a $5.00 price target on the stock.

A number of other equities research analysts have also recently issued reports on VNRX. Jones Trading upgraded VolitionRx to a "strong-buy" rating and set a $3.00 price objective on the stock in a research note on Tuesday, June 10th. Wall Street Zen began coverage on VolitionRx in a report on Thursday, May 15th. They set a "sell" rating for the company. One analyst has rated the stock with a sell rating, one has given a hold rating, two have given a buy rating and one has issued a strong buy rating to the company's stock. According to MarketBeat.com, VolitionRx currently has an average rating of "Moderate Buy" and a consensus target price of $3.50.

VolitionRx Stock Up 1.6%

Shares of NYSE:VNRX traded up $0.01 during midday trading on Friday, hitting $0.69. The stock had a trading volume of 28,764 shares, compared to its average volume of 196,334. The business's 50-day simple moving average is $0.70 and its 200-day simple moving average is $0.59. VolitionRx has a 12 month low of $0.40 and a 12 month high of $0.94. The company has a market cap of $72.16 million, a P/E ratio of -1.93 and a beta of 1.26.

Insider Buying and Selling at VolitionRx

In related news, Director Guy Archibald Innes bought 78,125 shares of the business's stock in a transaction that occurred on Tuesday, August 5th. The shares were acquired at an average cost of $0.64 per share, with a total value of $50,000.00. Following the completion of the purchase, the director directly owned 966,814 shares in the company, valued at $618,760.96. The trade was a 8.79% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Cameron John Reynolds bought 78,125 shares of VolitionRx stock in a transaction dated Tuesday, August 5th. The stock was acquired at an average price of $0.64 per share, with a total value of $50,000.00. Following the purchase, the chief executive officer directly owned 2,609,847 shares of the company's stock, valued at approximately $1,670,302.08. This represents a 3.09% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders acquired a total of 188,750 shares of company stock worth $118,175 over the last quarter. Company insiders own 10.40% of the company's stock.

Institutional Investors Weigh In On VolitionRx

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Armistice Capital LLC boosted its holdings in VolitionRx by 3.5% during the second quarter. Armistice Capital LLC now owns 8,493,074 shares of the company's stock valued at $6,455,000 after purchasing an additional 286,644 shares in the last quarter. Northwestern Mutual Wealth Management Co. bought a new stake in shares of VolitionRx in the 2nd quarter valued at about $52,000. Blair William & Co. IL acquired a new position in shares of VolitionRx during the 2nd quarter worth approximately $30,000. Silverberg Bernstein Capital Management LLC boosted its position in shares of VolitionRx by 42.8% during the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 200,782 shares of the company's stock worth $153,000 after acquiring an additional 60,209 shares in the last quarter. Finally, Millennium Management LLC bought a new position in shares of VolitionRx during the fourth quarter valued at $36,000. 8.09% of the stock is currently owned by institutional investors and hedge funds.

About VolitionRx

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes.